Genetic, transcriptomic, and epigenetic data reveal molecular mechanisms tying these disorders to each other and to immune disfunction.

The US Food and Drug Administration has called for a federal investigation of its own regulatory review process after widespread criticism of its decision on Aduhelm.

A lackluster performance in clinical trials of the monoclonal antibody aducanumab has left some experts unconvinced of its benefit.

Understanding how the brain coordinates electrical activity could be key to developing more-effective treatments for a variety of brain disorders.

A dysfunctional lymphatic system, described as a clogging of the brain’s sink, may explain why immunotherapies fail in some Alzheimer’s patients.

Authors of a new review urge researchers to consider how the chromosomal sex of a cell affects experiments in research on neurodegeneration.

Patients who received the drug fared better cognitively and functionally than those taking placebo, but still experienced losses in performance.

Manipulating the production of new neurons can improve cognition in animal models of the disease, raising the possibility that figuring out a way for humans to make more neurons could make a difference for people with dementia.

Knocking out the receptor for a lipid that causes inflammation rejuvenates macrophage metabolism and restores cognitive function in an Alzheimer’s disease model.

Neanderthal DNA surprises in modern humans, the first blood test for Alzheimer’s, a discovery of new human salivary glands, and, oh yeah, a pandemic

Brain cells in older Drosophila tend to have more than two complete sets of chromosomes, and that polyploidy most likely has a protective function, a study shows.

The variant causes a buildup of BACE1 protein in axons in cultured neurons and mice. Researchers say it might be time to rethink failed trials that inhibit BACE1 to treat the neurodegenerative disease.

The test will be a cheaper and more accessible alternative to currently available diagnostic tools, researchers say.

An imaging agent reveals aggregated tau protein in the brain during PET scans and could improve the diagnosis of neurodegenerative diseases, particularly tauopathies.

These “coarse-grained” plaques resemble those that clog up the brain’s blood vessels in a different disease, pointing to links between the vascular system and the neurodegenerative disease.